Company Encyclopedia
View More
name
CR Double-Crane
600062.SH
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China.
3.155 T
600062.SHMarket value -Rank by Market Cap -/-

Financial Score

10/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking15/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE14.69%A
    • Profit Margin14.44%B
    • Gross Margin58.72%B
  • Growth ScoreD
    • Revenue YoY-4.06%D
    • Net Profit YoY-6.23%C
    • Total Assets YoY2.83%C
    • Net Assets YoY11.68%B
  • Cash ScoreC
    • Cash Flow Margin692.74%C
    • OCF YoY-4.06%D
  • Operating ScoreB
    • Turnover0.65B
  • Debt ScoreB
    • Gearing Ratio28.52%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CR Double-Crane: Some drugs are proposed to be selected for national centralized drug procurement

    CR Double-Crane announced that the company and some of its subsidiaries participated in the 11th batch of national centralized drug procurement, and some products are expected to be selected. The drugs expected to be selected include Metoclopramide Injection, Meprobamate Injection, Famotidine Injection, and Piracetam Oral Immediate Release Formulation. Among them, the expected selected price for Metoclopramide Injection is 0.68 yuan per unit, for Meprobamate Injection is 9.78 yuan per unit, for Famotidine Injection is 0.42 yuan per unit, and for Piracetam Oral Immediate Release Formulation is 7.87 yuan per bottle

    Zhitong·
    SH
    600062
    -0.38%
    Zhitong·
    SH
    600062
    -0.38%

    CR Pharmaceutical: CR Double-Crane's net profit for the first three quarters is 1.388 billion yuan, a year-on-year decrease of 1.7%

    According to the Zhitong Finance APP, CR Pharmaceutical announced that CR Double-Crane achieved a total operating revenue of 8.283 billion yuan (RMB, the same below) for the nine months ending September 30, 2025, a year-on-year decrease of 3.1%; net profit was 1.388 billion yuan, a year-on-year decrease of 1.7%

    Zhitong·
    SH
    600062
    -0.38%
    Zhitong·
    SH
    600062
    -0.38%

    CR Double-Crane: The net profit for the third quarter was 374 million yuan, a year-on-year increase of 6.71%

    CR Double-Crane announced that its revenue for the third quarter was 2.542 billion yuan, a year-on-year decrease of 2.96%; net profit was 374 million yuan, a year-on-year increase of 6.71%. Revenue for the first three quarters was 8.283 billion yuan, a year-on-year decrease of 3.10%; net profit was 1.35 billion yuan, a year-on-year decrease of 3.40%

    Zhitong·
    SH
    600062
    -0.38%
    Zhitong·
    SH
    600062
    -0.38%

    CR Double-Crane's subsidiary Alpha Calcifediol Soft Capsules has obtained a drug registration certificate

    CR Double-Crane's wholly-owned subsidiary WanHui Double-Crane recently obtained the Drug Registration Certificate for Alfacalcidol Soft Capsules issued by the National Medical Products Administration. This medication is indicated for the treatment of various calcium metabolism disorders caused by endogenous 1,25-dihydroxyvitamin D3 deficiency, including renal osteodystrophy, hypoparathyroidism, and osteoporosis

    Zhitong·
    SH
    600062
    -0.38%
    Zhitong·
    SH
    600062
    -0.38%

    CR Double-Crane's subsidiary Bosentan dispersible tablets have obtained a drug registration certificate

    CR Double-Crane's wholly-owned subsidiary CR Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd. recently received the Drug Registration Certificate for Bosentan Dispersible Tablets issued by the National Medical Products Administration. This medication is suitable for pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension (PAH), as well as adult PAH patients classified as WHO functional class II to IV

    Zhitong·
    SH
    600062
    -0.38%
    Zhitong·
    SH
    600062
    -0.38%
    © 2025 Longbridge｜Disclaimer